Podcast

Turning Poop to Gold: Jenny Yang, Outpost Bio

Turning Poop to Gold: Jenny Yang, Outpost Bio

Jenny Yang's Live Interview on Ventures- Discussing how the poop science, AI, and the $3.5M pre-seed leading to Outpost's success.

Jenny Yang's Live Interview on Ventures- Discussing how the poop science, AI, and the $3.5M pre-seed leading to Outpost's success.

Outpost Bio Co-Founder and CEO Jenny Yang joined Raj to talk about Outpost’s mission to make human microbiology computable—and why the microbiome could be a critical missing layer in understanding how people respond differently to drugs, food, and other interventions.

The conversation covers:

  • Why differences in the gut microbiome may help explain why two people with the same genetics and the same medication can have very different outcomes

  • How Outpost combines purpose-built biological datasets with AI models to predict how microbial communities interact with drugs, food, and other molecules

  • How a better understanding of the microbiome could push personalized medicine beyond human genomics alone

  • How pharma, biotech, and consumer R&D teams can use microbiome data to understand efficacy, side effects, and differences across populations

  • Why Jenny sees advances in biological measurement and AI as an opportunity to tackle persistent challenges in drug development and human health

Outpost Bio Co-Founder and CEO Jenny Yang joined Raj to talk about Outpost’s mission to make human microbiology computable—and why the microbiome could be a critical missing layer in understanding how people respond differently to drugs, food, and other interventions.

The conversation covers:

  • Why differences in the gut microbiome may help explain why two people with the same genetics and the same medication can have very different outcomes

  • How Outpost combines purpose-built biological datasets with AI models to predict how microbial communities interact with drugs, food, and other molecules

  • How a better understanding of the microbiome could push personalized medicine beyond human genomics alone

  • How pharma, biotech, and consumer R&D teams can use microbiome data to understand efficacy, side effects, and differences across populations

  • Why Jenny sees advances in biological measurement and AI as an opportunity to tackle persistent challenges in drug development and human health

Related articles